Wedbush analyst, Tao Levy, reiterated his Outperform rating on shares of DexCom (NASDAQ: DXCM) but cut the price target to $100 from $112 due to near-term uncertainty that Medtronic’s product launches have created on near-term purchasing patterns of diabetes technology. However, the analyst remains optimistic that growth should improve in 2017.

As mentioned on both Tandem Diabetes (NASDAQ: TNDM) and DexCom’s earnings’ calls, the fourth quarter has started off weaker than expected for the aforementioned reason.

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $77.92 yesterday.